Debut

Debut (Debut Biotechnology, Inc.) is a San Diego-based biotechnology company that combines artificial intelligence, genomics and biomanufacturing to discover, validate and scale ingredients and formulations for the beauty industry. The company decodes skin and hair biology at the genomic level and translates those insights into novel bioactive ingredients, which it develops into finished, brand-ready formulations using clinically validated actives.

Its AI discovery platform, branded BeautyORB, is described as drawing on 2 billion proprietary data points, screening about 20,000 molecules per minute and evaluating a candidate space of roughly 96 billion molecular possibilities; the company states it has identified high-performing novel ingredients from that candidate pool without wet-lab experiments and reports 200-plus new pathways evaluated and four best-in-class molecules in market. Debut says its in-house skin health datasets reached 99 percent data consistency versus 85 percent for publicly available datasets, and it is targeting novel chemical entities rather than existing natural ingredients, with an ingredient focus on the 14 hallmarks of aging and "skin longevity."

Debut has released a series of DermCeutical branded actives — Naringenin (inflammaging, 2023), DHK (barrier support, 2024), EDL (skin tightening, 2025) and PNar (skin brightening, 2026) — and operates a vertically integrated model with a San Diego headquarters and pilot plant built in 2022 to commercialize rare and natural ingredients. In addition to supplying ingredients and formulations to beauty brand partners, it launched its own consumer skincare brand, DEINDE, in January 2024 as a proof of concept, and has moved into contract manufacturing.

Founding story

Debut was founded in 2019 by Joshua Britton with a $100,000 seed investment from Linda, a former Uber passenger of Britton's. Britton, who holds an MS in Organic Chemistry from the University of Nottingham, a PhD in Organic Chemistry from UC Irvine and a postdoctoral fellowship in Chemistry at MIT, developed the intellectual property underlying the company's AI-powered biomanufacturing platform, and the company licensed patents from MIT and UC Irvine.

Business model

Debut develops proprietary ingredients and formulations and commercializes them through beauty brand partners, positioning itself as an outsourced formulation-innovation provider so brands can adopt biotech ingredients without heavy upfront R&D expense. It also engages in product contract manufacturing and operates its own consumer skincare brand, DEINDE.

Revenue is generated from supplying ingredients and formulations to beauty brand partners, contract manufacturing of finished products, and direct consumer sales through the DEINDE brand.

Traction

Reported traction includes four best-in-class molecules in market, over 200 new pathways evaluated, cumulative funding of $85 million as of August 2025, a San Diego headquarters and pilot plant, partnerships with L'Oréal (more than a dozen bio-identical ingredients) and Natura (Latin America), and the DEINDE consumer brand which the CEO said was on track to meet or exceed its 2025 targets.

Latest developments

In August 2025 Debut announced a $20 million raise supported by Fine Structure Ventures, EDBI, Wealthberry, L'Oréal's BOLD fund, GS Futures, Sandbox Industries and Material Impact, to fund AI ingredient discovery targeting the 14 hallmarks of aging and to scale its formulation business in the US and Asia, beginning with Singapore. The company subsequently announced a partnership with Natura to commercialize an AI-discovered skin longevity ingredient in Latin America, launched DermCeutical EDL and DermCeutical PNar, and expanded into hair and body care.